Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) CEO John Treace bought 39,944 shares of Treace Medical Concepts stock in a transaction on Thursday, August 20th. The stock was purchased at an average price of $4.44 per share, with a total value of $177,351.36. Following the completion of the acquisition, the chief executive officer directly owned 7,388,383 shares of the company’s stock, valued at $32,804,420.52. This represents a 0.54% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Treace Medical Concepts Stock Performance
TMCI stock opened at $4.37 on Tuesday. The firm has a market cap of $284.22 million, a price-to-earnings ratio of -4.70 and a beta of 1.37. The firm has a 50-day simple moving average of $4.36 and a two-hundred day simple moving average of $2.91. Treace Medical Concepts, Inc. has a one year low of $1.17 and a one year high of $7.78. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.95 and a current ratio of 2.90.
Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. The firm had revenue of $45.38 million for the quarter, compared to the consensus estimate of $44.02 million. On average, equities analysts forecast that Treace Medical Concepts, Inc. will post -0.83 EPS for the current fiscal year.
Institutional Investors Weigh In On Treace Medical Concepts
Analyst Ratings Changes
Several brokerages have weighed in on TMCI. Wall Street Zen raised Treace Medical Concepts from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings cut shares of Treace Medical Concepts from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. Finally, Truist Financial upped their price target on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the company a “hold” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $5.17.
Get Our Latest Analysis on Treace Medical Concepts
About Treace Medical Concepts
Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.
The Lapiplasty System has received clearance from the U.S.
Further Reading
- Five stocks we like better than Treace Medical Concepts
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
